Provided by Tiger Trade Technology Pte. Ltd.

Monte Rosa Therapeutics

13.38
-0.9400-6.56%
Post-market: 13.380.00000.00%19:30 EDT
Volume:884.65K
Turnover:12.09M
Market Cap:1.14B
PE:-7.67
High:14.30
Open:14.29
Low:13.37
Close:14.32
52wk High:25.77
52wk Low:4.60
Shares:85.31M
Float Shares:54.48M
Volume Ratio:0.72
T/O Rate:1.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7450
EPS(LYR):-0.4650
ROE:-42.66%
ROA:-21.63%
PB:2.34
PE(LYR):-28.78

Loading ...

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 06

Monte Rosa Therapeutics announces annual shareholder meeting

Reuters
·
Apr 30

What You Need To Know About The Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Analyst Downgrade Today

Simply Wall St.
·
Apr 21

Monte Rosa Therapeutics to present preclinical data on MRT-55811

TIPRANKS
·
Apr 20

Monte Rosa presents CCNE1 degrader data at AACR meeting

Reuters
·
Apr 20

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors

GlobeNewswire
·
Apr 20

Top Executive’s Surprise Move Shakes Up Monte Rosa Therapeutics Insider Activity

TIPRANKS
·
Apr 16

Monte Rosa CEO Markus Warmuth disposes 8,000 shares for $141,120

Reuters
·
Apr 16

Top Monte Rosa Therapeutics Executive Makes Notable Insider Stock Move

TIPRANKS
·
Apr 11

Monte Rosa Chief Business & Legal Officer Philip Nickson sells 5,845 shares for $103,410

Reuters
·
Apr 11

Monte Rosa Therapeutics Inc : Jefferies Assumes Coverage With Buy Rating; Target Price $30 VS $31

THOMSON REUTERS
·
Mar 30

A Look At Monte Rosa Therapeutics (GLUE) Valuation After Johnson & Johnson MRT-2359 Trial Supply Agreement

Simply Wall St.
·
Mar 28

A Look At Monte Rosa Therapeutics (GLUE) Valuation After Its Recent Share Price Pullback

Simply Wall St.
·
Mar 21

J.P. Morgan Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)

TIPRANKS
·
Mar 19

Monte Rosa Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 18

Monte Rosa Therapeutics Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Mar 18

Wells Fargo Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE)

TIPRANKS
·
Mar 18

Sector Update: Health Care Stocks Mixed Premarket Tuesday

MT Newswires Live
·
Mar 17

Monte Rosa Therapeutics Inc. publishes corporate presentation on molecular glue degrader pipeline with three clinical programs

Reuters
·
Mar 17

Monte Rosa Q4 net loss widens 244% to USD 46.14 million on revenue down 95% to USD 2.78 million

Reuters
·
Mar 17